Introduction
Eczema or atopic dermatitis (AD) is a chronically relapsing dermatosis that affects 9% to 20% of children in the US and is more prevalent in children who belong to upper socio-economic classes, smaller family sizes, and families with overzealous hygiene. [1] [2] [3] [4] [5] [6] [7] The disease affects 5.6% of young children and 3.8% of school children and adolescents in Hong Kong. 8, 9 Children with AD may suffer from lack of sleep, irritability, daytime tiredness, emotional stress, lowered self-esteem, and psychological disturbance. 10, 11 The disruption of school, family life, and social interactions can severely impair the quality of life and extends beyond childhood. Parents may experience guilt, frustration, resentment, exhaustion, and helplessness due to their child's condition. 12 The diagnosis of AD is predominantly clinical, based on a constellation of clinical features. Firm criteria to define AD were first established by Hanifin and Rajka. 2, 13 The UK working diagnostic criteria are also concise and practical. mediated immunity related to an imbalance in two subsets of CD4-T cells that creates a predominance of T-memory cells in the T-helper 2 pathways and preferential apoptosis of interferon-gamma producing T-helper 1 memory and effector Tcells. 15 , 16 Recently, we demonstrated that AD also involves many cellular and humoral immune mediators in addition to an aberration of cellmediated immunity. 17 There is a strong genetic predisposition. It has been shown that loss-of-function mutations in the filaggrin (filament-aggregating protein) [FLG] gene predispose to AD. [18] [19] [20] [21] [22] Recent findings have shown that the affected skin of atopic individuals is deficient in filaggrin degradation products. 23, 24 In summary, AD is an atopic/allergic disease that involves complex interactions among susceptible genes, immunological factors, skin barrier defects, infections, neuroendocrine factors, and environmental factors. 2 Using clinical guidelines primarily but not exclusively from Europe, the US, Australia, Canada, Hong Kong, Korea and Japan, this paper summarises the contemporary therapeutics in management of childhood AD.
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induce disease exacerbation and justify additional antimicrobial treatment. Adjuvant therapy includes ultraviolet (UV) irradiation preferably with UVA1 or narrowband UVB. Dietary recommendations should be specific and given only when food allergy is confirmed. Allergen-specific immunotherapy against aeroallergens may be useful in selected cases. Parallel use of traditional and proprietary topical and herbal medicine has also been popular in China and many cities in Asia. Complementary and alternative medicine may have a place but evidence-based data are lacking. 
Overview of atopic dermatitis therapeutic guidelines
Reviews and guidelines on management of AD have been published by various professional organisations worldwide. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Most of the guidelines have provided recommendations for both children and adults while the National Institute for Health and Care Excellence (NICE) Guidelines focus on management of AD for children of 12 years and younger. 36, 38 These evidence-based guidelines are regularly reviewed and updated. The NICE guidelines were reviewed in 2011 and 2014 with no new recommendations or changes. The American Academy of Dermatology first published the guidelines in 2004 and recently updated them in 2014 with a more comprehensive review that was divided into four sections with paediatric considerations highlighted in the section on management and treatment with phototherapy and systemic agents. [29] [30] [31] [32] [33] 39 The new European Guidelines published in 2012 27,28 evaluated existing evidence-based guidelines from Germany, the Health Technology Assessment Report, and the position statement of the European Task Force on Atopic Dermatitis 26 together with an appraisal of updated literature to provide consensus recommendations for management. In 2013, the Hong Kong College of Paediatricians formed a panel group with paediatricians and dermatologists to agree on management guidelines of AD in children based on the NICE guidelines for children with recommendations for local practice. 40 
Overview of individual treatment

Emollient
Although emollients are widely recommended as the foundation in management of AD, their use is supported by only limited evidence. [41] [42] [43] [44] [45] There is no evidence to show that any emollient is superior to their counterparts. A small-scale randomised controlled trial (RCT) showed that over-the-counter petroleum-based skin protectant moisturiser for mild-to-moderate AD in children has similar clinical efficacy and much higher cost-efficacy than the glycyrrhetinic acid-containing barrier repair cream or a ceramide-dominant barrier repair cream. 46 Recently concern has been raised about the possible adverse effects of sodium lauryl sulphate (SLS), a surfactant commonly found in many emollients like aqueous cream and emulsifying ointments. Aqueous cream has been shown to cause skin irritation, thinning of the cornea stratum, and increased transepidermal water loss following twice daily application for a few weeks. [47] [48] [49] Hence, SLScontaining emollients are more suitable as a soap substitute rather than left-on emollients. There is a lack of evidence for other bathing practices like addition of emollients to bathing water, while use of emollients immediately after bathing as 'soak and seal' can help maintain hydration. 30, 45 Generally, liberal use of emollients is recommended but it is uncertain whether their use in between periods of eczema flare-up helps to prevent further deterioration and how different methods and timing of application of emollients influence their efficacy.
The Barrier Enhancement for Eczema Prevention research study (http://beepstudy.org) aims to find out whether skin care advice including application of emollients can prevent eczema in newborns. A pilot study identified 124 infants with high-risk factors for AD including more than one first-degree relative with a history of asthma, hay fever, or AD. 50 Subjects were randomised to receive once-daily application of an emollient before the age of 3 weeks and continuing for 6 months. The 6-month cumulative incidence of investigator-diagnosed eczema was 22% in the daily emollient group compared with 43% in controls corresponding to a relative risk reduction of 50%. 50 Another prospective RCT to investigate whether protecting the skin barrier with a moisturiser during the neonatal period could prevent development of AD and allergic sensitisation showed that daily application of moisturiser during the first 32 weeks of life reduces the risk of AD/eczema in infants. 51 These reports suggest that use of emollients might prevent development of AD in high-risk patients.
Topical corticosteroids
Evidence for the use of topical corticosteroids (TCS) in the management of AD is well established. 52 Topical corticosteroids are recommended as firstline anti-inflammatory therapy for AD in children and adults. 27, 30, 35, 40 The TCS are classified in order of relative potency according to their vasoconstrictive effect. 30, 40 Different formulations of the same agent affect the potency, with ointment, cream, and lotion in descending order of clinical efficacy. There are limited clinical studies to compare the different types of TCS and evidence for recommendations on dosage, frequency, and duration of application is sparse. The choice of type and formulation of TCS depends on a number of factors including severity and site of lesions, patient's age and preference. The NICE guidelines for children recommend use of the corresponding potency of TCS for severity of atopic eczema; mild potency for the face and neck and moderate potency only for short-term (3-5 days) use in severe flares; moderate or potent preparations for short periods only (7-14 days) for flares in vulnerable sites such as axillae and groin. 36, 53 Potent fluorinated corticosteroids should be avoided for infants and sensitive skin areas. 34 Systematic reviews of studies that compared the frequency of application of newer-generation moderately potent to very potent steroids identified no benefit in outcome for more frequent applications over once-daily application. 54 In general, TCS should be applied once daily and no more than twice daily. 36, 38, 53 During acute flares, it is advisable to use the strength and potency of steroids appropriate to the severity of the eczema daily to gain rapid control of inflammation, reducing gradually with a less-potent steroid or less-frequent application.
Topical corticosteroids are generally safe with few serious reported adverse effects. 55, 56 Risks of side-effects increase with higher potency, occlusion, thinner skin areas, severity of AD, young age, and longer duration of use. Local adverse effects include skin atrophy, telangiectasia, hypertrichosis, and striae. 56 Skin absorption of TCS sufficient to cause clinical significant systemic adverse effects are rare. A systematic review of small-scale studies on the effects of hypothalamic-pituitary-adrenal (HPA) axis in children using TCS showed an overall good safety profile with a few cases demonstrating HPA suppression associated with use of potent TCS. Reports on effects of growth delay were inconclusive. 57 Clinical monitoring of potential sideeffects of TCS is sufficient and routine monitoring of systemic side-effects is not recommended. Steroid phobia is a common cause of failure of treatment. 58, 59 Parental concerns should be addressed to ensure adherence to treatment. 60 Systematic review of seven case-control and cohort studies on pregnant women using TCS did not demonstrate an association of TCS with congenital abnormality or adverse outcome of pregnancy.
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Wet-wrap
Use of wet-wrap treatment was first described in detail in the early 1990s. Wet-wrap treatment involved application of TCS, with or without dilution, and emollients under layers of wet dressings. The principles of action included increase in TCS effects under occlusion, maintenance of skin hydration, cooling of inflamed skin, and reduction of scratching. 62 Devillers and Oranje 63 reviewed 10 small-scale studies with two RCTs and eight observation studies of wet-wrap treatment in children with moderate-to-severe eczema. All except one study applied undiluted mild TCS (hydrocortisone) or diluted mild-to-potent steroid (1:5 to 1:50 dilution) cream or ointment under two layers (one wet layer and one dry layer) of tubular bandages, maintained for 3 to 24 hours a day for a period of 2 to 14 days. There were variations in the type of steroid, emollient, and dressing used for wet-wrap, but all studies reported improvement in eczema scores. 63 One study used emollients combined with 0.5% chlorhexidine and also showed mild improvement in SCORAD (SCORing Atopic Dermatitis) score after 3 days of treatment. A recent RCT showed that wetwrap with diluted 1% mometasone ointment had a better outcome and acted faster than emollients only. 64 The most common reported adverse effects include discomfort, mostly due to chills, and folliculitis more commonly caused by ointment. Six out of the 10 studies reported a temporary decrease in early morning serum cortisol that normalised afterwards. 63 Most experts recommended wet-wrap with diluted steroids as a short-term second-line treatment for severe eczema after infection was controlled. A set of practice guidelines on wetwrap treatment was published by the same group of authors with a detailed description of methodology and materials used. 62 Nonetheless climacteric and personal issues limit the usefulness of wet-wrap treatment outside of the hospital setting. 65 
Topical immunomodulants
Topical calcineurin inhibitors (TCI) are ascomycin macrolactam derivatives produced by Streptomyces strains of bacterium. Topical calcineurin inhibitors act through inhibition of calcineurin function and hence reduce the production and release of proinflammatory cytokines in AD. Pimecrolimus cream 1% and tacrolimus ointment 0.03% are licensed for use in patients older than 2 years. Tacrolimus ointment (0.1%) is recommended for use only over the age of 15 years and it remains part of the current recommendations by the US Food and Drug Administration (FDA). [66] [67] [68] [69] Short-term (3-12 weeks) and long-term (up to 1 year) studies of both TCIs showed that TCIs were significantly more effective than vehicle. [40] [41] [42] Tacrolimus studies included mostly patients with moderate-to-severe AD and pimecrolimus studies focused on mild-to-moderate AD. [66] [67] [68] There is strong evidence that TCIs have a steroid-sparing effect and long-term use of up to 12 months can prevent flares. 66 Topical calcineurin inhibitors are particularly useful for sensitive sites including the face, neck, and skin flexures. Tacrolimus has been objectively shown to reduce itch and ameliorate sleep disturbance. 70 Three studies that directly compared the efficacy of pimecrolimus and tacrolimus involved mainly children with mild-to-severe AD and showed that tacrolimus was more effective than pimecrolimus. 66, 68 In comparing TCI and TCS, a few short-term paediatric studies showed that 0.03% and 0.1% tacrolimus ointment was more effective than 1% hydrocortisone acetate cream or ointment. 66, 68 Two paediatric studies showed that 1% pimecrolimus is more effective than 1% hydrocortisone acetate and 0.1% triamcinolone acetate. 68 One adult study showed that pimecrolimus was less effective than moderate TCS. 67 In long-term studies of children and adults, TCIs were well tolerated. The most common sideeffects were local irritation, erythema, or pruritus. 66 There was no evidence of increase in skin infections or skin atrophy even when TCIs were applied under occlusion. Systemic absorption was low and serum level did not accumulate following application for up to 12 months. Nonetheless data from animal studies on the risks of cancer associated with TCIs and post-marketing reports of lymphoma and skin cancer led the US FDA to issue recommendations for TCIs as short-term non-continuous therapy of AD in non-immunocompromised patients aged 2 years or above, 69 and approved a black-box warning label for the two TCIs pimecrolimus cream (1%) and tacrolimus ointment (0.03% and 0.1%) in 2006. 66 Subsequently, the efficacy and safety of TCIs have been systematically reviewed by various authors and professional groups: most concluded that TCIs are safe without evidence of increased risk of malignancy. 55, 66, 69, 71, 72 At the moment, data from available human case-control and cohort studies have identified no causal association of TCIs with malignancies although the long-term potential carcinogenic risks of TCIs remain uncertain. Most international guidelines recommend that clinicians alert patients/parents to the black-box warning before starting treatment. 26, 30, 36 The latest guidelines of the American Academy of Dermatology recommend off-label use of 0.03% tacrolimus ointment and 1% pimecrolimus for patients younger than 2 years with mild-to-severe AD.
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Proactive approach with topical anti-inflammatory therapy
Atopic dermatitis is a chronic relapsing inflammatory condition. Use of topical anti-inflammatory medications (TCS or TCI) intermittently only during acute flares and maintenance therapy with emollients during periods of clinical remission has been a common treatment strategy. Nonetheless, visually normal skin may have subclinical inflammation and be prone to exacerbations. There has been a paradigm shift in the approach to prevent flares through low-dose topical maintenance and proactive therapy after stabilisation of an acute exacerbation. 32, 73 A systematic review identified eight RCTs of proactive treatment with four trials of tacrolimus, three trials of fluticasone propionate, and one of methylprednisolone aceponate in paediatric and adult patients suffering from moderate-to-severe AD. 74 Study medications were applied once daily twice a week (except one study of tacrolimus with application 3 times a week) over a period up to 16 weeks and 40 weeks for TCS and TCI, respectively. The data showed that the proactive treatment approach was more efficacious in prevention of flares during the treatment period but long-term safety data are lacking. 74 The results suggested that for a patient with moderate-to-severe eczema and chronic relapsing lesions, maintenance treatment with topical anti-inflammatory therapy twice a week may be a better strategy to prevent AD flares and TCS may be more effective than TCIs.
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Topical sodium cromoglicate
Sodium cromoglicate (SCG) has anti-allergic, antiitch, and anti-inflammatory properties. It has been used topically in the treatment of asthma, allergic rhinitis, and allergic conjunctivitis. Recently, the effect of a new formulation of 4% SCG cutaneous emulsions was evaluated as treatment for children with AD. 75 A meta-analysis of three multicentre RCTs involving 490 children with AD and a mean age of 5.3 years compared the outcomes of application of SCG emulsion against vehicle over a 12-week period. 75 There was significant improvement in SCORAD score within the treatment group and 4% SCG produced a more significant but clinically mild difference in SCORAD score of -2.82 (-5.36; -0.29), P=0.03. 75 Another RCT of 208 children aged 2 to 12 years over 12 weeks showed that 4% SCG was more effective in terms of greater improvement in SCORAD and SASSAD (Six Area, Six Sign Atopic Dermatitis) severity scores and reduced use of topical steroids during treatment periods. 76 These results suggested that 4% SCG emulsion could be an effective treatment for children with AD.
Antimicrobials and antiseptics
There is no doubt that Staphylococcus aureus is linked to AD and treatment with short-course oral antibiotics in infected AD is a common practice despite the lack of supportive evidence. 77, 78 A systematic review included 26 short-term lowquality studies of 1229 AD participants and compared various interventional strategies to reduce S aureus infection, including oral antibiotics, topical antibiotics, or topical anti-septics. 79 The authors concluded that anti-staphylococcal strategies can reduce the amount of bacteria in skin but the clinical benefit, especially in non-infected AD, remains uncertain. Large-scale long-term good-quality studies are needed to study clinical outcomes and adverse effects. One study involved 31 children (6 months to 17 years) with moderateto-severe AD and evidence of bacterial infection who were randomised to use diluted bleach bath of 0.005% sodium hypochlorite twice per week plus nasal mupirocin 5 days per month for 3 months. 80 Bacteria count was reduced and there was significant improvement in mean eczema EASI (Eczema Area and Severity Index) scores compared with placebo at 1 month and 3 months. 80 Recent guidelines have included diluted bleach bath and nasal mupirocin as a recommended treatment for patients with moderate-to-severe AD and clinical signs of secondary bacterial infection.
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Antihistamines
Relief of itch will help to break the 'itch-scratch cycle' in AD. Despite the widespread use of first-and second-generation H1 antihistamines in AD, there is no strong evidence that oral antihistamines are effective anti-pruritics. 81 They are safe to use and their sedative effects, where present, may be useful to promote better sleep quality.
Systemic immunomodulating therapy
In patients with moderate-to-severe eczema who fail to respond to topical therapy, systemic immunomodulating agents have been prescribed as off-label medications. The European Treatment of Severe Atopic Eczema in Children Taskforce conducted a survey on the use of systemic therapy across eight European countries. 82 Overall, 343 consultant physicians responded with 89.2% dermatologists: 71% would initiate systemic immunosuppression for children with severe atopic eczema. Cyclosporin A (CsA; 43.0%) was the most popular first-line drug followed by oral corticosteroids (30.7%) and azathioprine (AZA; 21.7%); CsA (33.6%) and AZA (28.7%) were the two most commonly used as second-line medication, while methotrexate (MTX) was ranked as the most popular third-line drug (26.2%). 82 Around half of the respondents (53.7%) replied that they routinely test and treat cutaneous infection prior to starting systemic treatment and 78.3% used penicillins as the first choice of antibiotics. 82 Roekevisch et al 83 recently published an updated systematic review based on Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology, on the efficacy and safety of 12 systemic treatment interventions for moderate-to-severe AD. Overall, 34 RCTs were selected comprising a total of 1653 paediatric and adult patients. It concluded that CsA, AZA, and MTX could be recommended as systemic treatment for refractory AD. There were 14 short-term and long-term studies on CsA that all demonstrated improvement in clinical outcomes, and short-term studies had the largest number of subjects for the strongest recommendations. Although the authors recommended CsA as a first-line therapy, AZA as second-line, and MTX as third-line systemic treatment for moderate-to-severe AD, there was a lack of data on direct comparison of the efficacy of these three agents. 83 In addition, paediatric data were scant and the long-term safety profile of these medications in AD patients was uncertain. Clinicians should consider patient factors and potential risks when prescribing any one of the above systemic agents. Recommendations were not possible for other systemic treatment including mycophenolate mofetil, intravenous gamma globulin, montelukast, systemic calcineurin inhibitors, and systemic corticosteroids due to limited or poor-quality data. Systemic oral glucocorticosteroids were used for years but the high risk of flares after cessation of treatment and unfavourable risk-benefit profile limited their clinical use, especially in children.
Cyclosporin A
Cyclosporin A inhibits activation of T cells and has been originally used to control graft rejection in transplant patients. With accumulating experience and data about its role in the treatment of severe AD, international guidelines recommend CsA as a systemic immune therapy to consider for chronic severe eczema in children and adults who have failed to respond to topical therapy. 28, 33, 34 Five RCTs with 146 participants compared CsA with placebo and revealed an improvement in clinical eczema severity scores by 53% to 95% after treatment from 10 days to 8 weeks. 84 One study also showed a decrease in surface area of involvement. 84 In a systematic review of 15 controlled and uncontrolled studies including 602 patients, cyclosporin consistently decreased the severity of atopic eczema. 83 Analysis of 12 studies found a dose-related response at 2-week treatment with a pooled mean decrease in disease severity of 22% (95% confidence interval [CI], 8-36%) with low-dose cyclosporin (<3 mg/kg) and 40% (95% CI, 29-51%) at dosages of ≥4 mg/kg. After 6 to 8 weeks, the relative effectiveness was 55% (95% CI, 48-62%). 83 A few studies compared CsA with other agents and showed it to be more effective than oral prednisolone, intravenous immunoglobulin (Ig), and phototherapy. 81 There were four open-label paediatric and adult long-term studies for CsA of up to 12 months showing sustained effects with continuous use. 81 The potential side-effects of CsA in AD are similar to those in other conditions that require CsA therapy. They include infection, nephrotoxicity, hypertension, hypertrichosis, gingival hyperplasia, increased risks of skin cancer and lymphoma. Patients should have their blood pressure checked at every visit with renal and liver function tests, and blood cell counts performed every 2 weeks for the first 2 to 3 months of treatment, then monthly thereafter. The usual dosage recommendations of CsA ranged from 2.5 to 6 mg/kg/day although a higher initial starting dosage of 5 mg/kg/day demonstrated a more rapid response and adverse effects were not reported to be dose-related. Nonetheless on balance, it is advisable to start at a lower dose of 2.5 to 3 mg/kg/day and titrate stepwise to ascertain the lowest maintenance dose for control with serum creatinine within 25% of baseline. 28, 33 As the long-term safety profile and relapse rate of CsA use in AD patients, in particular paediatric patients, is uncertain, it may be more suitable as a short-term therapy. Concomitant use of other immunosuppressants or phototherapy is not recommended.
Azathioprine
Azathioprine is a purine analogue with immunomodulating properties. Similar to CsA, it was initially developed in the 1960s for treatment of graft-versus-host disease. In the past 20 years evidence has accumulated for its use as a steroid-sparing agent in the treatment of severe recalcitrant AD. Two RCTs in 98 adult patients found better improvement in SASSAD score following AZA treatment for up to 12 weeks compared with placebo. 83 A study comparing AZA with MTX showed similar improvement in symptom scores and quality of life after 12 weeks of treatment. 83 Paediatric data were limited but a few observational studies showed promising results. A local retrospective study of 17 children and young adults showed improved SCORAD score at 3 months and 6 months of treatment. 85 Dosage recommendations ranged from 1 to 3 mg/kg/day. Mild side-effects such as gastro-intestinal intolerance and headache are common. Serious sideeffects have been linked to genetic polymorphism of thiopurine methyltransferase (TPMT), an important enzyme in the metabolism of AZA. Individuals with homozygous TPMT mutations (low or absent TPMT activity) are prone to develop life-threatening myelosuppression while those with supra-normal TPMT activity may respond less well to treatment but could be at higher risk of hepatotoxicity. 33 The dosing of AZA can also be guided by TPMT activity as patients with TPMT activity at the heterozygous range respond at the low dosage range with no increase in toxicity. 86 Measurement of TPMT level before initiation of treatment with AZA is generally recommended and regular monitoring of blood cell counts and liver function tests is indicated for all patients during the course of treatment.
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Methotrexate
Methotrexate is a folic acid antagonist with T-cell suppression, approved for use in two dermatological conditions including psoriasis and advanced mycosis fungoides. A few small-scale retrospective studies showed that MTX was effective in the treatment of AD adult patients. 33, 83 There were only a few paediatric retrospective case series demonstrating that MTX treatment in AD was safe, effective, and well tolerated. 33 Recently, El-Khalawany et al 87 published the first RCT study comparing low-dose MTX (7.5 mg/week) and CsA (2.5 mg/kg/week) in 40 Egyptian children with severe AD. At the end of 12 weeks, there was a similar reduction in mean SCORAD score for MTX and CsA. The study showed 20% to 30% of patients on MTX had minor adverse effects of anaemia, fatigue and diarrhoea, and 20% had abnormal liver but none had significant liver toxicity or other adverse effects that required adjustment in treatment.
Phototherapy
Garritsen et al 88 performed the first systematic review of phototherapy in AD patients using GRADE system. Nineteen RCT studies of various modalities of photo(chemo)therapies with treatment duration of 10 days to 40 weeks involving 905 participants (age range, 8-83 years) were included. Metaanalysis could not be performed as most studies were small scale with wide heterogeneity in quality and methodology. The authors concluded that narrowband ultraviolet B (NB-UVB) and ultraviolet A1 (UVA1) seemed to be the most effective forms of phototherapy. 88 Psoralen plus UVA (PUVA) was also an effective option but generally not the first choice due to its association with side-effects. Other treatment modalities including full-spectrum UVA, broadband UVB, and full-spectrum light therapy were considered less effective treatment. Most forms of phototherapy were mainly used for treatment of chronic lichenified forms of moderateto-severe AD, except for high-dose UVA1 that was also effective for treatment of acute flares. 88 In general, long-term exposure to UV light increases the risk of skin cancer. One report highlighted an increased risk of non-melanoma skin cancer in children with psoriasis on PUVA treatment. 33 There are, however, no data about the long-term risk of developing cancer in children undergoing NB-UVB. 89 Common reported side-effects included xerosis cutis, erythema, burning sensations, and skin pigmentation. Ultraviolet A treatment, particularly with the addition of oral psoralen (PUVA), was more likely to be associated with side-effects of photosensitivity, cataract formation, folliculitis, and photo-onycholysis. Side-effects of oral psoralen include headache, nausea, vomiting, and, rarely, hepatotoxicity. Concomitant therapy with emollients and TCS may be used for control of acute flare and maintenance therapy but TCI should be avoided. In current guidelines, phototherapy is considered a safe and effective second-line treatment for moderateto-severe AD. 28, 33, 34 Available evidence supports NB-UVB as the preferred treatment with moderatedose UVA1 as an alternative treatment, while highdose UVA1 may be considered in the acute phase. Clinical response to the type, dose, and duration of phototherapy varied widely and treatment regimens have to be individualised.
Dietary interventions
The relationship of food allergy with AD is complex. 90, 91 Immunoglobulin E sensitisation to food has been reported in about 40% to 90% of patients with moderate-to-severe AD, but positive skin prick testing and specific IgE levels have poor predictive value for immediate or delayed eczematous reactions. 91, 92 Dietary avoidance based on food-specific IgA or IgG testing is not efficacious in ameliorating disease severity. 93 Food allergens trigger eczema exacerbations especially in infants and young children but there is a lack of evidence that food allergens cause AD. A systematic review of the effects in nine trials of an elimination diet on existing eczema showed that there was no evidence to support the use of egg-free or milk-free dietary exclusion for unselected AD patients and no benefit for elemental or food-restricted diet in general. 94 An exclusion diet is more likely to be useful in patients with a clinical history of IgE-mediated allergic reactions and young patients with severe disease. 94 An elimination diet should not be continued if no improvement is observed after 3 to 4 weeks. 
Allergen-specific immunotherapy
Administration of allergen-specific immunotherapy (ASIT) through giving repeated incremental subcutaneous (SCIT) or sublingual (SLIT) doses of allergen may induce immune tolerance in patients sensitised to allergens. In patients with AD, the best evidence for use of ASIT is with the house dust mite (HDM) allergen. In a systematic review, eight RCTs that comprised a total of 385 AD subjects sensitised to HDM were given ASIT: six studies used SCIT and two studies used SLIT for a treatment period of 4 to 36 months. It was found that ASIT had a significant positive effect on clinical outcome of AD. 95 The effect was significant in subgroup analysis for long-term treatment longer than 1 year, severe AD and SCIT, but insignificant for children only and SLIT. 95 Nonetheless with the limitations of smallscale heterogeneous studies, it is not possible to make specific recommendations on the use of ASIT. Current evidence suggests that ASIT may be one of the treatment options in patients with severe AD sensitised to HDM. 28, 34 Chinese herbal medicine
The beneficial effects of Chinese herbal medicine (CHM) in children with AD have not been consistently demonstrated. 96, 97 Meta-analyses have been performed by Cochrane reviews and show no conclusive evidence that oral intake of most Chinese herbs or Chinese herbal formulae used in the included studies could improve eczema. 96 Further, they could not find convincing evidence that topical application of CHM, used alone or in conjunction with oral administration of Chinese herbal formula, could reduce the severity of eczema in children or adults. Even though the included studies claimed that there were statistically significant differences in the outcome measures for the CHM treatment groups compared with the control groups, these claims could not be substantiated due to a low strength of evidence and high risk of bias. 98 In a series of studies and a RCT, Hon et al [99] [100] [101] [102] demonstrated that a PentaHerbs concoction improved quality of life in children with moderateto-severe eczema. Experts in the Cochrane reviews have suggested that well-designed, adequately powered trials are needed to evaluate the efficacy and safety of CHM for managing eczema.
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Psychological and educational interventions
Psychological symptoms of stress, anxiety, and depression are prevalent among eczema patients and correlate with quality-of-life impairment. 104 Psychological and educational interventions are complementary to other therapeutic approaches to help patients and carers to cope with this chronic condition. These interventions were reviewed systematically and recently updated by the Cochrane Skin Group in 2014. 105 Ten studies were included with nine studies reviewing predominantly parentfocused educational interventions and one focused on child-centred psychological interventions. 105 One large study of 992 subjects revealed that the study group who received age-appropriate group education in six standardised sessions had significant improvement in disease severity score and quality of life. 105 Due to the heterogeneity of interventions and outcome, the authors concluded that it was impossible to draw definitive conclusions and there was a need for further research, in particular standalone psychological interventions.
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Conclusion
Management of AD has remained challenging, often not because of the lack of effective treatment but of non-adherence and unrealistic expectations on the part of patients or their parents. Detailed evaluation of disease severity, treatment history, and its impact on patients' and parents' quality of life will determine the individual success of management for this complex atopic disease.
